Gabriel ETIENNE
Centre for Human Drug Research · University Hospital Bordeaux, France
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gabriel ETIENNE as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:38 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04592536 · A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy SubjectsCerevel Therapeutics, LLC · completed · Panic Disorder · principal investigator
- Ph2NCT01774630 · Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)University Hospital, Bordeaux · completed · Leukemia, Myelogenous, Chronic, BCR-ABL Positive · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:38 UTC. The ranking covers the 200 most relevant of 26 PubMed records, and a shared surname and initials can bring in a namesake. All 26 on PubMed
- Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.N Engl J Med · 20101,328 citationsRCR 30.4
- 1,245 citationsRCR 27.8
- 648 citationsRCR 22.0
- 501 citationsRCR 12.3
- 340 citationsRCR 9.6
- Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.N Engl J Med · 2010305 citationsRCR 6.8
- 299 citationsRCR 9.2
- 292 citationsRCR 16.9
- Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.Lancet Oncol · 2016222 citationsRCR 7.5
- Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.N Engl J Med · 2024156 citationsRCR 21.1